Q-Line Biotech Limited

Depreciation for the Year ended March 31, 2025 was ₹ 732.12 Lakhs.

## Other expenses

Other Expenses for the year ended March 31, 2025 stood at ₹ 6341.96 Lakhs.

## Restated Profit before tax:

The Company reported Restated profit before tax for year ended March 31, 2025 of ₹ 4419.23 Lakhs.

## Restated profit after tax:

The Company reported Restated profit after tax for Year ended March 31, 2025 of ₹ 2813.09 Lakhs.

## Comparison of Financial Year 2025 with Financial Year 2024 (Based on Restated Financial Statements)

### Total Income

Our total income has increased by 56.25% to ₹ 32258.42 lakhs in fiscal 2025 from ₹ 20644.81 lakhs in Fiscal 2024. The total income has increased as the revenue from the operations has increased due to the increased business from the existing and new customers. Further our core areas of clinical chemistry and Haematology has seen higher growth in the revenues. Our clinical chemistry contributed 10,692.87 lakhs in the FY 24 which increased to 18,999.53 lakh in the financial, which witnessed growth of 77.68%. Similarly, Haematology segment has seen the growth 28.77% and the revenue increased from 6507.13 lakhs to 8379.31 lakhs.

### Revenue from Operations

Our revenue from operations has increased by 54.08% to ₹ 31378.04 lakhs in Fiscal 2025 from ₹ 20364.61 lakhs in Fiscal 2024. The total income has increased as the revenue from the operations has increased due to the increased business from the existing and new customers. Further our core areas of clinical chemistry and Haematology has seen higher growth in the revenues. Our clinical chemistry contributed 10,692.87 lakhs in the FY 24 which increased to 18,999.53 lakh in the financial, which witnessed growth of 77.68%. Similarly, Haematology segment has seen the growth 28.77% and the revenue increased from 6507.13 lakhs to 8379.31 lakhs.

### Other Income

Our other income was ₹ 280.20 lakhs in Fiscal 2024, which has increased by 214.20% to ₹ 880.38 lakhs in Fiscal 2025. The main reason for such increase is the increase in the interest income on fixed deposits and write back of the liabilities no longer required.

### Expenses

Our total expenses have increased by 48.67% to ₹ 26142.66 lakhs in Fiscal 2025 from ₹ 17584.65 lakhs in Fiscal 2024. The main reason for increase is the business efficiency on account of increase in the revenue which resulted into stabilized expenses in comparison to the total income of the company.

### Cost of Goods sold

The cost of goods sold increased from ₹ 9301.95 lakhs to 14566.98 lakhs representing an increase of approximately 56.60%. The main reason for increase in the cost of goods sold was due to increase in the Revenue. The cost to service ratio change in the portion of product mix of the company.

### Employee benefits expenses

Employee benefit expenses increased by 29.08% from ₹ 2348.63 lakhs in Fiscal 2024 to ₹ 3031.59 lakhs in Fiscal 2025. Such increase was due to new employees hired in the different departments due to the increased production and volumes of the company.

### Depreciation and amortization expenses

Depreciation, and amortization expenses increased by 86.40% from ₹ 392.77 lakhs in Fiscal 2024 to ₹ 732.12 lakhs in Fiscal 2025. The company works on high capex model which requires company to invest regularly in the fixed assets, that is why the expenses of the company has increased for dep and amortization.